Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes.

Many of the vital actions of thrombin on platelets and other cells appear to be mediated by the recently cloned seven-transmembrane-domain thrombin receptor. Thrombin activates this receptor by a novel proteolytic mechanism. The amino-terminal exodomain of the receptor contains the sequence LDPRSFLLRNPNDKYEPF. Structure-activity studies with mutant receptors and receptor peptides suggest that this sequence binds to thrombin at two sites: LDPR with the active center of thrombin and KYEPF with the fibrinogen recognition exosite of thrombin. Thrombin then cleaves the Arg41-Ser42 bond to unmask a new amino terminus, which functions as a tethered peptide ligand binding to as yet undefined sites within the body of the receptor to effect receptor activation. We have determined eight crystal structures of thrombin complexed with receptor-based peptides. Each of the two components of the bidentate docking model was captured in individual cocrystals. In one crystal type, the LDPR sequence docked in the active center of thrombin in a manner analogous to d-PheProArg chloromethyl ketone. In other crystals, the KYEPF sequence bound in the fibrinogen anion binding exosite of thrombin in a manner analogous to the DFEEI sequence of the carboxylate-terminal peptide of hirudin. Strikingly, however, generation of a single crystal that includes both components of the anticipated bidentate binding mode was not achieved, apparently because the peptides have a dominant solution S-like conformation that does not bind in a productive way at the active center. This peptide structure apparently favored a novel alternative mode of receptor peptide-thrombin interaction in which the receptor peptides formed an intermolecular bridge between neighboring thrombin molecules, resulting in an infinite peptide thrombin chain in crystals. In this structure, the KYEPF sequence docked in the expected manner at the exosite of one thrombin molecule, but the LDPR sequence docked in an unusual nonproductive mode with the active center of a neighboring molecule. Mutations that removed important determinants of the S-like receptor peptide structure underlying the bridging mode in the receptor itself did not significantly alter thrombin signaling. Additionally, a comparison of receptor density to the responsiveness of a cell did not support a role for receptor oligomerization in signaling. The physiological role for this unexpected intermolecular binding mode, if any, remains to be identified.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  H Oschkinat,et al.  The interaction of thrombin with fibrinogen. A structural basis for its specificity. , 1992, European journal of biochemistry.

[2]  B. Finzel Incorporation of fast Fourier transforms to speed restrained least‐squares refinement of protein structures , 1987 .

[3]  Mary L. Westbrook,et al.  Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. , 1991 .

[4]  V. Wheaton,et al.  Domains specifying thrombin–receptor interaction , 1991, Nature.

[5]  R. Feinman,et al.  Interrelations of platelet aggregation and secretion. , 1977, The Journal of clinical investigation.

[6]  W. Bode,et al.  Crystal structure of the thrombin‐hirudin complex: a novel mode of serine protease inhibition. , 1990, The EMBO journal.

[7]  G. Eichele,et al.  Diffraction methods for biological macromolecules. Seed enlargement and repeated seeding. , 1985, Methods in enzymology.

[8]  J. Sheehan,et al.  Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  C. Esmon,et al.  Glu-192----Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Huber,et al.  The structure of residues 7-16 of the A alpha-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution. , 1994, The Journal of biological chemistry.

[11]  E. Lüscher,et al.  Release reactions of human platelets induced by thrombin and other agents. , 1968, Biochimica et biophysica acta.

[12]  J. Maraganore,et al.  Hirulog peptides with scissile bond replacements resistant to thrombin cleavage. , 1991, Biochemical and biophysical research communications.

[13]  J. Maraganore,et al.  Anticoagulant activity of synthetic hirudin peptides. , 1989, The Journal of biological chemistry.

[14]  Solution structure of a platelet receptor peptide bound to bovine alpha-thrombin. , 1992, Biochemistry.

[15]  A. Tulinsky,et al.  Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors. , 1994, Biochemistry.

[16]  H Brandstetter,et al.  Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. , 1992, Journal of molecular biology.

[17]  J. Fenton,et al.  Analysis of the secondary structure of hirudin and the mechanism of its interaction with thrombin. , 1988, Archives of biochemistry and biophysics.

[18]  M. Zabinski,et al.  Anion-binding exosite of human alpha-thrombin and fibrin(ogen) recognition. , 1988, Biochemistry.

[19]  B. Kobilka,et al.  Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling. , 1993, The Journal of biological chemistry.

[20]  C. Esmon,et al.  The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. , 1991, The Journal of biological chemistry.

[21]  Robert Huber,et al.  The refined 1.9 A crystal structure of human alpha‐thrombin: interaction with D‐Phe‐Pro‐Arg chloromethylketone and significance of the Tyr‐Pro‐Pro‐Trp insertion segment. , 1989 .

[22]  R. Huber,et al.  The structure of a complex of recombinant hirudin and human alpha-thrombin. , 1990, Science.

[23]  Barry C. Finzel,et al.  The use of an imaging proportional counter in macromolecular crystallography , 1987 .

[24]  A Tulinsky,et al.  Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor. , 1993, The Journal of biological chemistry.

[25]  Axel T. Brunger,et al.  Extension of molecular replacement: a new search strategy based on Patterson correlation refinement , 1990 .

[26]  D. Turk,et al.  The refined 1.9‐Å X‐ray crystal structure of d‐Phe‐Pro‐Arg chloromethylketone‐inhibited human α‐thrombin: Structure analysis, overall structure, electrostatic properties, detailed active‐site geometry, and structure‐function relationships , 1992, Protein science : a publication of the Protein Society.

[27]  R. Huber,et al.  Refined structure of the hirudin-thrombin complex. , 1991, Journal of molecular biology.

[28]  J. Maraganore,et al.  Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. , 1990, Biochemistry.

[29]  K C Nicolaou,et al.  Molecular basis for the inhibition of human alpha-thrombin by the macrocyclic peptide cyclotheonamide A. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Hendrickson Stereochemically restrained refinement of macromolecular structures. , 1985, Methods in enzymology.

[31]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.

[32]  J. Maraganore,et al.  Thrombin-specific inhibition by and slow cleavage of hirulog-1. , 1992, The Biochemical journal.